Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes

Abstract

This study used Taiwan's National Health Insurance claim database (years 2000-2005) to examine how thiazolidinediones (TZD), a new class of drugs for diabetes, penetrated into Taiwan's hospitals, and its association with the concentration of all diabetes drugs at the hospital level. We collected 72 monthly summaries of diabetes prescriptions from all hospitals in Taiwan. Hospital-level pharmaceutical concentration was measured by penetration of TZD, defined as monthly market share of TZD in each hospital. Concentration of diabetes drugs was measured by Herfindahl-Hirschman indices. We found a negative association (coefficient = -0.3610) between TZD penetration and concentration of diabetes drug but a positive association between penetration of TZD and the volume of prescribed diabetes drugs (coefficient = 0.4088). In conclusion, hospital characteristics and volume of services determined the concentration of pharmaceuticals at the institution level, reflecting the heterogeneous competition between pharmaceutical companies within each hospital. Institution-level pharmaceutical concentration influences the adoption and penetration of new drugs.

The structure of the pharmaceutical market in Iran using concentration indices

“…Exclusivity can have negative effects on the welfare of the society. Market concentration makes it difficult for new products to easily get into the market and thus it decreases the accessibility (16). The lack of exclusivity in the pharmaceutical market in Iran can be considered as a strong point to improve the efficiencies of this section.…”

Decision to adopt medical technology under the National Health Insurance System in Taiwan: case study of new molecular targeted drugs among non‐small cell lung cancer patients

“…Our results echo Lund et al . 's research findings [13] that patients with advanced cancer are more likely to receive new modality of treatment. However, compared with patients with stage 4 NSCLC, patients with stage 3B NSCLC were more likely to receive MTD (adjusted OR = 1.58; 95% CI = 1.17–2.14).…”

Thiazolidinedione use in elderly patients with type 2 diabetes: with and without heart failure

“…In addition, the variation in the frequency of prescribing TZD, might have been influenced by pharmaceutical marketing at various levels of healthcare. Tsai et al 21. found that the intense commercial pressures, at different levels of care, influenced the prescription of new, higher‐priced anti‐diabetic drugs, including TZD.…”